论文部分内容阅读
目的探讨不同剂量乌司他丁对心肺复苏后患者的疗效。方法心肺复苏后患者36例,上述患者均为心脏骤停后经心肺复苏后自主循环恢复,且能存活超过72 h患者。上述患者随机分为观察组和对照组。观察组和对照组患者各18例。两组患者均给予常规的心肺复苏抢救措施,给予常规的心肺复苏常规急救药物,两组患者用药相同。患者在心肺复苏自主循环恢复后,观察组患者给予乌司他丁,40万U/次,2次/d。对照组患者给予乌司他丁,20万U/次,2次/d。观察两组患者多器官功能衰竭发生情况,记录两组患者治疗28 d后生存情况。结果观察组患者多器官功能衰竭发生6例,发生率为33.3%;对照组患者多器官功能衰竭发生12例,发生率为66.7%;观察组多器官功能衰竭发生率低于对照组,差异有统计学意义(P<0.05);观察组治疗后28 d生存共13例,生存率为72.2%;对照组患者治疗后28 d生存共7例,生存率为38.9%。观察组患者治疗28 d后生存率高于对照组,差异有统计学意义(P<0.05)。结论应用乌司他丁有助于提高心肺复苏后患者的生存率,且较大剂量乌司他丁的临床治疗效果优于较小剂量,值得借鉴。
Objective To investigate the efficacy of different doses of ulinastatin in patients after cardiopulmonary resuscitation. Methods Thirty-six patients after cardiopulmonary resuscitation (CPR) were recovered spontaneously after CPR and survived for more than 72 hours after cardiac arrest. The above patients were randomly divided into observation group and control group. 18 cases in observation group and control group. Both groups were given routine cardiopulmonary resuscitation (CPR) rescue measures, routine CPR rescue medication, and the two groups were given the same medication. Patients in the cardiopulmonary resuscitation spontaneous circulation recovery, the observation group was given ulinastatin, 400000 U / times, 2 times / d. Patients in the control group were given ulinastatin 200,000 U / time 2 times daily. The incidence of multiple organ failure in both groups was observed, and the survival of the two groups was recorded after 28 days of treatment. Results In the observation group, 6 cases occurred in multiple organ failure, the incidence was 33.3%. In the control group, 12 cases occurred multiple organ failure, the incidence was 66.7%. The incidence of multiple organ failure in the observation group was lower than that in the control group, the difference was (P <0.05). In the observation group, 13 cases survived 28 days after treatment and the survival rate was 72.2%. In the control group, there were 7 cases survived 28 days after treatment and the survival rate was 38.9%. The survival rate of the observation group was higher than that of the control group 28 days after treatment, the difference was statistically significant (P <0.05). Conclusion Ulinastatin can improve the survival rate of patients after cardiopulmonary resuscitation, and the higher dose of ulinastatin is superior to the smaller dose of clinical treatment, it is worth learning.